News Sentiment

ABSI sentiment intelligence

Absci Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 8.30 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-21.7% over one week, +11.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Absci (NASDAQ:ABSI) Stock Price Down 7.6% - Should You Sell?

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -21.7% Price reacting lower
Trend fit Trend active 11.9% over four weeks
Fair value 129.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 28
Neutral 26
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 8
Investing.com 6
TradingView 5
simplywall.st 4
Quartr 3
MarketBeat 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 19
Analyst action 7
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
MarketBeat Direct company coverage

Absci (NASDAQ:ABSI) Stock Price Down 7.6% - Should You Sell?

Absci (NASDAQ:ABSI) shares dropped 7.6% in mid-day trading following a period of mixed analyst sentiment, despite some analysts raising price targets and maintaining buy ratings. The company's recent earnings report showed better-than-expected EPS but significantly missed revenue

Tone
Negative 40/100
Event
Earnings
Published
16 Jul 2026 16:41
Source
MarketBeat
GlobeNewswire Direct company coverage

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

Absci Corporation, a clinical-stage biopharmaceutical company, announced it will report business updates and financial results for the second quarter of 2026 after market close on Tuesday, August 11, 2026. A conference call and webcast will follow the announcement to discuss deve

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 14:10
Source
GlobeNewswire
scanx.trade Direct company coverage

Absci to report Q2FY26 results on August 11, 2026

Absci Corporation will release its Q2FY26 financial results and host a conference call on August 11, 2026, to discuss its business updates, financial performance, and future outlook. The clinical-stage biopharmaceutical company, which utilizes generative AI for drug design, is ad

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 23:12
Source
scanx.trade
Stock Titan Direct company coverage

Absci sets 4:30 p.m. ET webcast for its Aug. 11 Q2 update

Absci (Nasdaq: ABSI) will report its second quarter 2026 financial and operating results on Tuesday, August 11, 2026, after market close. Management will host a webcasted conference call at 4:30 p.m. Eastern Time to discuss business developments, financial performance, and outloo

Tone
Positive 58/100
Event
Earnings
Published
14 Jul 2026 20:12
Source
Stock Titan
Market source Direct company coverage

Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know

Wall Street analysts predict a 28.3% upside for Absci Corporation (ABSI), with an average price target of $13.6 and a standard deviation indicating general agreement. While price targets alone are not a reliable investment guide due to potential optimism and business incentives,

Tone
Positive 72/100
Event
Analyst action
Published
14 Jul 2026 01:16
Source
Market source
MarketBeat Direct company coverage

Wall Street Zen Downgrades Absci (NASDAQ:ABSI) to Sell

Wall Street Zen downgraded Absci (NASDAQ:ABSI) from a "hold" to a "sell" rating, despite several other analysts recently raising their price targets and maintaining "buy" ratings, leading to an overall "Moderate Buy" consensus. The downgrade followed Absci's quarterly results, wh

Tone
Neutral 50/100
Event
Analyst action
Published
12 Jul 2026 18:39
Source
MarketBeat
Quartr Direct company coverage

Absci (ABSI) Morgan Stanley 22nd Annual Global Healthcare Conference Summary

Absci (ABSI) discussed its strategic transition from a platform technology company to an AI-driven drug creation firm at the Morgan Stanley 22nd Annual Global Healthcare Conference. The company is now focusing on developing a proprietary pipeline with generative AI for antibody d

Tone
Positive 74/100
Event
Market update
Published
08 Jul 2026 23:39
Source
Quartr
Quartr Direct company coverage

Absci (ABSI) Morgan Stanley 23rd Annual Global Healthcare Conference Summary

Absci highlighted its strategic focus on leveraging AI for generative design to tackle challenging drug targets, aiming to reduce development timelines and costs while advancing novel biology. The company discussed its pipeline, including ABS-101 and ABS-201, with key clinical re

Tone
Positive 76/100
Event
Market update
Published
08 Jul 2026 11:39
Source
Quartr
Quartr Direct company coverage

Absci (ABSI) Q4 2024 earnings summary

Absci (ABSI) made significant progress in 2024, advancing internal programs and securing new partnerships. Financially, Q4 2024 revenue was $0.7 million, with a full-year revenue of $4.5 million, and the company ended the year with $112.4 million in cash, expected to fund operati

Tone
Positive 63/100
Event
Earnings
Published
08 Jul 2026 11:39
Source
Quartr
Investing.com Nigeria Direct company coverage

Absci director Mary T Szela buys $148,866 in stock By Investing.com

Absci Corp director Mary T Szela recently purchased 12,900 shares of company common stock for $148,866. This transaction increased her direct ownership to 21,300 shares, occurring while the stock trades near its 52-week high and has seen a 319% return. The company is also advanci

Tone
Positive 66/100
Event
Market update
Published
07 Jul 2026 11:40
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Form 4 Absci Corp For: 6 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Absci Corp (ABSI) dated July 6. The brief piece includes the company's stock symbol and a small negative percentage change for the day, indicating it's a routine financial filing announcement.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 11:11
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Absci (ABSI) director buys 12,900 shares in open-market trade

Absci Corp. director Mary T. Szela purchased 12,900 shares of Common Stock at $11.54 per share on June 30, 2026, in an open-market transaction. This transaction increased her direct ownership to 21,300 shares, as detailed in the SEC Form 4 filing. The purchase was executed in acc

Tone
Positive 75/100
Event
Market update
Published
06 Jul 2026 19:40
Source
Stock Titan
Investing.com Direct company coverage

Absci director Mary T Szela buys $148,866 in stock

Absci Corp (NASDAQ:ABSI) director Mary T Szela purchased 12,900 shares of company common stock for $148,866 on June 30, 2026, increasing her direct ownership to 21,300 shares. This insider purchase comes as Absci trades near its 52-week high after a significant 319% return over t

Tone
Positive 66/100
Event
Market update
Published
06 Jul 2026 16:18
Source
Investing.com
Sahm Direct company coverage

Is Absci (ABSI) Undervalued On Encouraging ABS 201 Phase 1 Data?

Absci (ABSI) is experiencing strong short-term momentum with its stock up over 221% year-to-date, driven by encouraging interim Phase 1 data for its investigational drug ABS-201 and a recent US$100 million equity offering. While one narrative suggests the company is 6.3% underval

Tone
Positive 66/100
Event
Regulatory and legal
Published
05 Jul 2026 23:10
Source
Sahm
TradingView Direct company coverage

Enterprise value to revenue forward of Absci Corporation – NASDAQ:ABSI

This article provides the enterprise value to revenue (forward) for Absci Corporation (NASDAQ: ABSI). It specifies the period, the value, and the percentage change for this financial metric. The information is presented by TradingView, sourcing data from ICE Data Services and Fac

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 11:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Absci Corporation – NASDAQ:ABSI

This article provides a view of Absci Corporation's (NASDAQ: ABSI) financial data, specifically focusing on its forward price-to-sales ratio. It briefly lists essential financial and market information available on TradingView for the company. The content appears to be a stub or

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 04:10
Source
TradingView
富途牛牛 Direct company coverage

BTIG Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $13

BTIG has reiterated its Buy rating for Absci Corp (ABSI.US) and maintained its target price at $13. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Tone
Positive 77/100
Event
Analyst action
Published
03 Jul 2026 01:10
Source
富途牛牛
GuruFocus Direct company coverage

ABSI Maintained by Truist Securities -- Price Target Raised to $17.00

Truist Securities has maintained a Buy rating for Absci (ABSI) and increased its price target from $11.00 to $17.00, indicating a bullish outlook. Despite this, GuruFocus assesses ABSI as significantly overvalued by 527.4% with a GF Value of $1.77 against its current price of $11

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 18:09
Source
GuruFocus
Simply Wall Street Direct company coverage

Absci (ABSI) Is Up 10.3% After Positive ABS-201 Phase 1 Data And $100M Equity Raise

Absci Corporation's stock (ABSI) rose 10.3% following positive interim Phase 1 data for its ABS-201 drug, which targets androgenetic alopecia, demonstrating favorable safety and a long half-life. Concurrently, the company completed a $100 million equity offering, providing capita

Tone
Positive 77/100
Event
Market update
Published
02 Jul 2026 14:09
Source
Simply Wall Street
TradingView Direct company coverage

Enterprise value to EBITDA forward of Absci Corporation – NASDAQ:ABSI

This article provides access to the enterprise value to EBITDA forward metric for Absci Corporation (NASDAQ:ABSI) through TradingView. It indicates that the market for ABSI was closed at the time of viewing, with no trades mentioned. The content primarily focuses on navigation an

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 17:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Absci Corporation – NASDAQ:ABSI

This article provides price-to-earnings forward data for Absci Corporation (NASDAQ: ABSI). It presents a table showing the period, value, and change percentage for this financial metric. The content is hosted on TradingView, indicating that it is a financial data point for invest

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 20:10
Source
TradingView
TradingView Direct company coverage

Absci Corporation Actuals & Estimates (NASDAQ:ABSI)

This article provides an overview of Absci Corporation (NASDAQ: ABSI) stock performance, financial actuals, and analyst estimates. It highlights recent stock price movements, market capitalization, future price forecasts, and key financial metrics including earnings, revenue, and

Tone
Positive 72/100
Event
Earnings
Published
29 Jun 2026 17:09
Source
TradingView